CELL INTELLIGENCE · 肿瘤细胞治疗研究

用于三阴性乳腺癌和膀胱癌免疫治疗的 TROP-2 双特异性 T 细胞衔接器的表征

Characterization of TROP-2 bispecific T cell engagers for immunotherapy of triple negative breast and bladder cancer.

膀胱癌免疫治疗的演变前沿：整合 BCG、免疫检查点、病毒载体、纳米技术与基于 CAR 的疗法

Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies.

ROR2 特异性 CAR-T 细胞对血液肿瘤和实体瘤有效且在小鼠中耐受良好

ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice.

感染作为腹膜后实性肿块鉴别诊断的病例系列及文献综述

Infection as a Differential Diagnosis of Solid Retroperitoneal Masses: A Case Series and Review of the Literature.

转移性尿路上皮癌中 HER2 靶向治疗的演变全景：系统综述与未来展望

The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives.

ERBB2 扩增可能成为 mUC 的一个新靶点，尽管其临床获益程度仍有待阐明。在这方面，新型 ADC 是最有前景的策略。ERBB2 突变仍处于临床研究的极早期阶段。